FDA Approves ROSUVASTATIN — Accord Healthcare Inc.

Accord Healthcare Inc. announced the FDA approval of its rosuvastatin calcium tablets, generating preliminary industry interest as a potential market entrant in the competitive oral cholesterol-lowering drug sector. This addition of a generic offering to the API supply chain is anticipated to foster pricing pressure within the rosuvastatin market.